智通财经APP获悉，德意志银行分析师周四给予阿斯利康(AZN.US)"卖出"评级，对该英国制药商的药物研发管线(尤其是乳腺癌疗法)持更为审慎的看法。
分析师伊曼纽尔·帕帕达基斯将该公司股票评级从"持有"下调，并将目标股价下调至105英镑，成为分析师中的最低目标价。这意味着较本月上半月强劲上涨后的当前水平有16%的下跌空间。
帕帕达基斯在报告中写道，"随着阿斯利康股价升至近期交易区间高位，我们借此机会转向更明确的看空，"他上一次对该股给出"买入"建议是在2023年7月。
该分析师认为，阿斯利康的关键乳腺癌药物camizestrant不太可能展现出比同类药物更显著的疗效。他补充称，由于专利到期压力开始加剧，当前估值可能过高。
与此同时，其他分析师对该制药商更为乐观，约四分之三给予"买入"建议，12个月平均目标股价超过140英镑。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.